An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
Price : $35 *
At a glance
- Drugs Aldoxorubicin (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CytRx Corporation
- 05 Jun 2017 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
- 16 Aug 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016.